Nezam El-Tayebat 事实核查对“نظام الطيبات”饮食体系的科学评估
选择国家
选择语言: 简体中文

正确 有充分科学证据支持 证据确定性: 高 初步 C-ODD-02

达格列净（Forxiga，安达唐）等SGLT2抑制剂可能引起酮症酸中毒，有时发生在血糖正常甚至偏低的情况下。

安全提示: 血糖升高同时尿液或血液中出现酮体（丙酮），尤其伴有恶心、呕吐、腹痛、呼吸急促、口渴或嗜睡时，可能意味着糖尿病酮症酸中毒，这是一种医疗急症。在使用SGLT2抑制剂（例如达格列净/Forxiga、恩格列净）的人中，酮症酸中毒可能在血糖正常、仅轻度升高甚至偏低时发生；长时间禁食、极低碳水化合物饮食、患病、脱水或减少胰岛素都会增加这一风险。请立即寻求急诊治疗；不要等待，也不要试图靠禁食熬过去。未经主治医生同意，请勿停用或更改糖尿病药物。
简而言之: 该说法正确。达格列净等SGLT2抑制剂会使原本罕见的糖尿病酮症酸中毒风险增加约一倍（5年内每1,000人约多2例），而且这种酮症酸中毒可能发生在血糖正常、或少数情况下血糖偏低时，尤其是在禁食期间；这是需要采取预防措施的理由，而不是证明这些药物总体有害的证据。
结论: 正确：达格列净等SGLT2抑制剂会使原本罕见的酮症酸中毒风险增加约一倍，这种酮症酸中毒可能在血糖正常甚至偏低时发生，尤其是在禁食期间；这要求采取预防措施，而不是回避一种已被证实有益的药物。
  1. 原始表述
  2. 科学评估
  3. 科学证据详解
  4. 通俗解释
  5. 与该说法相关的研究
  6. 地区背景
  7. 在我的国家适用什么？
  8. 参考文献

原始表述

الفروسيجا عمل نفس تاثير المجاعه على جسم حضرتك سكر طبيعي او تحت الطبيعي ومعاه كيتو اسيدوزيس

按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。

译文

达格列净（Forxiga，安达唐）等SGLT2抑制剂可能引起酮症酸中毒，有时发生在血糖正常甚至偏低的情况下。

出处

来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
الغيبوبات السكرية ؟! (打开来源)
发布日期
2025年4月30日
时间戳
0:10:54 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
所声称的机制

Glucose loss in urine mimics starvation; ketogenesis continues.

所声称的健康影响

Ketoacidosis (euglycaemic DKA)

涉及人群

SGLT2 inhibitor users

Elawady 设定的地域限制

none found

来源版本存在差异

来源状态
档案网站引语（未注明出处）
归属
Elawady (archive paraphrase; source video not given)
出处
https://eltayebat.com/rule/oral-diabetes-drugs/
归属的不确定性
The archive's 'د. ضياء يقول' box gives no video reference; wording is the archive's paraphrase.

ايه بتحصل فيها المجعات ومع المجهود البدني العنيف زي ده واحد دخل في مقاتله عنيفه حتى الموت او مجاعه استمدت لشهور او دواء مشهور قوي اسمه الفورسيجا الفورسيجا ده من اقذر من اقذر ما يمكن يعني انا ما شفتش ادويه اقذر منه غير

Forxiga (dapagliflozin) is among the 'dirtiest' drugs he has seen; like starvation lasting months or extreme physical exertion, it can lead to ketoacidosis.

来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
Dr.D Clinics - Diaa Al Awady is live! الغيبوبة الكيتونية (打开来源)
发布日期
2025年4月23日
时间戳
0:47:36 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.

科学评估

正确 – 该说法有可靠证据支持。

证据确定性: 高 – 进一步研究极不可能改变该评估。

1. 说法是什么？

Forxiga causes ketoacidosis even with normal glucose.

2. 哪些内容可证实是正确的？

The claim is correct. SGLT2 inhibitors about double the risk of DKA: OR 2.07 (1.44-2.98), high certainty, about 2 extra cases per 1,000 people over 5 years (I-ODD-107); RR 2.12 (1.49-3.04) in 13 large blinded trials, from a placebo rate of about 0.2 per 1,000 patient-years (I-ODD-106); with dapagliflozin specifically 0.3% vs 0.1% in DECLARE-TIMI 58 (I-ODD-105); cohort HR 2.85 vs DPP-4 inhibitors (I-ODD-09); adjudicated CREDENCE data 11 vs 1 cases (I-ODD-05). Ketoacidosis often presents with normal or only mildly raised glucose (median 10.6 mmol/L in 1,024 published cases, I-ODD-104; I-ODD-10), and 15 published cases occurred with glucose below 100 mg/dL, 11 of them after fasting or poor intake (I-ODD-128). ADA 2026 lists very-low-carbohydrate diets and prolonged fasting as risk factors and reports a 5-17-fold risk in type 1 diabetes (I-INS-10). The mechanism described (urinary glucose loss producing a starvation-like ketotic state) is the accepted explanation.

3. 哪些内容是错误或夸大的？

Nothing in this statement itself. The risk is rare in type 2 diabetes (about 0.2-2 per 1,000 patient-years) and does not make the drug net harmful: in the same trials dapagliflozin reduced heart-failure hospitalisation and kidney events (I-ODD-105) and death in heart failure and CKD (I-ODD-04, I-ODD-03); across 13 trials about 26 serious events were avoided for every 2 caused per 1,000 patient-years in CKD with diabetes (I-ODD-106). Elawady's conclusion that Forxiga is one of the 'dirtiest' drugs is assessed separately (C-ODD-06, FALSE).

4. 哪些内容仍不明确？

The ketoacidosis risk of SGLT2 inhibitors during prolonged fasting or very low-carbohydrate eating, as promoted in the system, has not been measured in trials; the data come from cohorts, case series and trial programmes. No risk estimates for Egyptian patients were found.

5. 哪些研究支持该说法？

I-ODD-107 (NMA, high certainty), I-ODD-106 (13 blinded RCTs), I-ODD-105 (DECLARE, dapagliflozin), I-ODD-103 (meta-analysis RR 2.46), I-ODD-05 (CREDENCE), I-ODD-09 (cohort), I-ODD-104 and I-ODD-10 (euglycaemic presentation), I-ODD-128 (low-glucose cases), I-INS-10 and I-ODD-16 (ADA 2026), A-ODD-10 and A-ODD-11.

6. 哪些研究与该说法相矛盾？

No high-quality evidence contradicts the DKA risk. A small Egyptian cohort found no DKA among 61 patients starting SGLT2 inhibitors during supervised Ramadan fasting (I-ODD-129), which is too small to exclude a rare event. Net-benefit evidence (I-ODD-02, I-ODD-03, I-ODD-04, I-ODD-106) concerns a different question (C-ODD-06).

7. 对德国和欧洲而言情况如何？

EMA/BfArM product information for SGLT2 inhibitors carries the same DKA warning (not separately fetched).

8. 关于埃及的已知情况是什么？

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

9. 合理的实际结论是什么？

糖尿病酮症酸中毒（DKA）的风险是真实存在的，这使得像 Tayebat 体系所建议的那样，把SGLT2抑制剂与长时间禁食、极低碳水化合物饮食或减少胰岛素结合起来尤其危险。ADA 2026建议，使用这些药物时应接受患者教育、检测酮体，并避免生酮饮食模式。正确的做法是在了解情况的基础上使用药物并遵守患病期间的用药规则，而不是拒绝一种已被证实对心脏和肾脏有益的药物。

评估详情

证据确定性的依据

High-certainty randomised evidence: a network meta-analysis of 816 RCTs rated the DKA increase with SGLT2 inhibitors as high certainty (OR 2.07, 1.44-2.98; about 2 more per 1,000 over 5 years) (I-ODD-107); a meta-analysis of 13 large blinded trials found RR 2.12 (1.49-3.04) in people with diabetes (I-ODD-106); in the dapagliflozin trial DECLARE-TIMI 58, DKA occurred in 0.3% vs 0.1% (I-ODD-105). Normal-glucose presentation is typical (median 10.6 mmol/L in 1,024 published cases, I-ODD-104), and rare cases occur with glucose below 100 mg/dL, mostly after fasting (I-ODD-128). Absolute risk in type 2 diabetes is low (about 0.2-2 per 1,000 patient-years) and higher in type 1 diabetes (ADA 2026: 5-17 times).

来源质量

Own words plus archive paraphrase; Elawady's description of euglycaemic ketoacidosis is essentially correct.

地区可推广性

Universal.

个体例外情况

Risk higher in type 1 diabetes/insulin deficiency, low-carbohydrate diets, fasting, surgery, acute illness, alcohol.

说法的地域范围
普遍性（生物学/医学）
最近审核
2026年10月26日 初步

科学证据详解

有充分科学证据支持 – 该说法与一致的高质量证据相符。

研究问题: In people taking SGLT2 inhibitors such as dapagliflozin, does the risk of diabetic ketoacidosis increase, and does ketoacidosis occur with normal or low blood glucose?

研究问题详解 (PICO)
人群
People with type 2 (and type 1) diabetes, and non-diabetic users for heart failure/CKD
干预或暴露
SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin)
对照
Placebo or other glucose-lowering drugs
地域范围
universal biology; fasting practices relevant to Egypt
结局指标
  • Diabetic ketoacidosis
  • Glucose level at DKA presentation
  • Precipitating factors (fasting, low-carbohydrate intake)

研究结果按作者报告呈现。我们的评估见下文。

哪些证据支持该说法？

哪些证据不支持该说法？

总体证据说明了什么？

基于上述研究的编辑评估——其本身并非研究结果。

哪种观点有更好的证据支持？

The claim is correct. SGLT2 inhibitors about double the risk of diabetic ketoacidosis (absolute risk about 0.2-2 per 1,000 patient-years in type 2 diabetes, higher in type 1 diabetes), and this ketoacidosis often presents with normal or only mildly raised glucose; rare cases occur with low glucose, mostly after fasting or poor food intake.

为什么有些研究权重更大

Randomised evidence (Shi 2023 NMA, SMART-C, DECLARE for dapagliflozin specifically) establishes the risk; case series establish the euglycaemic and hypoglycaemic presentations. The small Egyptian cohort is too small to weigh against this.

因果关系是否已确立？ 是，已确立 Randomised placebo-controlled trials show a consistent increase; the mechanism (glucosuria lowers insulin needs and raises glucagon, mimicking starvation ketosis) is accepted.

仍存在的不确定性

Absolute risk during prolonged fasting or very-low-carbohydrate eating has not been measured in trials.

合理的结论

The statement about ketoacidosis is true. It is a reason for precautions (sick-day rules, ketone testing, avoiding ketogenic diets and prolonged fasting without medical advice), not evidence that the drugs are net harmful (see C-ODD-06).

为什么研究结果看起来互相矛盾？

Palmer 2021 (BMJ NMA; not added) judged no DKA increase with moderate certainty, whereas the larger 2023 update by the same evidence programme (I-ODD-107) and SMART-C (I-ODD-106) found about a doubling with high certainty. The difference reflects more trials and events, not a true disagreement. The Egyptian Ramadan cohort (I-ODD-129) studied supervised short daytime fasting with education and dose adjustment, a different exposure from unsupervised prolonged fasting.

这是否取决于国家？
一般生物学效应
Drug pharmacology and physiology are universal.
饮食习惯
Prolonged fasting, Ramadan fasting and very-low-carbohydrate eating change the risk of hypoglycaemia and ketoacidosis with some drugs; relevant in Egypt and among Muslims in Europe.
食品原产地
Not applicable.
污染物
Not applicable.
本国生产条件
Not applicable (same active substances; generics widely used in Egypt).
法律规则
Drug labels and warnings are set by FDA/EMA and national regulators; Egyptian labelling not reviewed.
实际监测数据
No Egypt-specific pharmacovigilance data were found for this outcome.

足以改变结论的地区差异没有可靠数据支持。

统计复核
  • CI symmetry and absolute excess from placebo rate – RR 2.12 (1.49-3.04) symmetric; excess about 0.22 per 1,000 PY (0.10-0.41). 已重新计算
  • Absolute risk from OR and baseline 0.2% – 0.2% -> 0.41% over 5 years; 2.1 per 1,000 extra (paper: 2). 已重新计算
  • NNH from rounded DKA percentages – 0.3% vs 0.1% -> NNH about 500 over 4.2 years (rounding uncertainty). 已重新计算
  • CI symmetry – RR 2.46 (1.16-5.21) and 1.74 (1.07-2.83) symmetric. 已重新计算
总体证据的确定性（GRADE，简化版）
主要结局
Diabetic ketoacidosis with SGLT2 inhibitors vs placebo/comparators in type 2 diabetes
起始等级
高（随机试验）
结果
高

由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。

已核查的临床指南和官方声明
  • ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · 原始文献
    DKA uncommon in type 2 diabetes on SGLT2i (0.6-4.9 per 1,000 patient-years); RCT meta-analysis RR 2.46; risk factors include very-low-carbohydrate diets and prolonged fasting; type 1 diabetes risk 5-17 times higher; people on intensive insulin should not stop basal insulin even if not eating.
  • ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (Diabetes Care 2026;49 Suppl 1) (2026) · 原始文献
    Educate people at risk of DKA on SGLT inhibition about signs and risk mitigation, provide ketone testing tools and discourage a ketogenic eating pattern (rec. 9.39).
  • NICE: Type 2 diabetes in adults: management (NG28), last updated 18 February 2026 (2026) · 原始文献
    1 in 1,000 or fewer people would experience rarer events like DKA or Fournier gangrene; for most people benefits outweigh risks.
检索策略

本次审查的文献检索记录（检索式采用原数据库语法）。

数据库日期检索式检索目标命中数纳入数
Europe PMC2026年10月26日("SGLT2" OR "sodium-glucose cotransporter-2" OR "SGLT-2") AND ("diabetic ketoacidosis") AND ("meta-analysis") AND ("randomized" OR "randomised")支持性证据1724
PubMed2026年10月26日(euglycemic[tiab] OR euglycaemic[tiab]) AND ketoacidosis[tiab] AND (SGLT2[tiab] OR gliflozin*[tiab] OR dapagliflozin[tiab]) AND (systematic review[pt] OR meta-analysis[pt] OR systematic[ti])支持性证据9
PubMed2026年10月26日Colacci M[au] AND ketoacidosis[ti]支持性证据4
Europe PMC2026年10月26日(SGLT2 OR "SGLT-2" OR dapagliflozin OR empagliflozin) AND Ramadan AND (ketoacidosis OR ketone OR safety) AND (Egypt OR Arab OR Saudi OR Emirates OR "Middle East")双向174
PubMed2026年10月26日(dapagliflozin[ti] OR empagliflozin[ti] OR "SGLT2 inhibitors"[ti]) AND (ketoacidosis[tiab]) AND (placebo[tiab]) AND (randomized controlled trial[pt]) AND 2019:2026[dp]反对性证据21
Europe PMC2026年10月26日(TITLE:"SGLT2" OR TITLE:"SGLT-2" OR TITLE:"sodium-glucose") AND (mortality OR "kidney outcomes") AND ("meta-analysis") AND ("randomised" OR "randomized") AND PUB_YEAR:[2021 TO 2026]反对性证据1300
PubMed2026年10月26日(Egypt*[tiab]) AND (SGLT2[tiab] OR "SGLT-2"[tiab] OR dapagliflozin[tiab] OR empagliflozin[tiab]) AND (ketoacidosis[tiab] OR safety[tiab] OR adverse[tiab] OR Ramadan[tiab])双向4
ADA Standards of Care 2026, Section 6 (PubMed Central)2026年10月26日Fetched https://pmc.ncbi.nlm.nih.gov/articles/PMC12690178/; keyword review: SGLT, euglycemic, ketoacidosis. The diabetesjournals.org DOI landing pages returned HTTP 403; the identical article was read in PubMed Central.指南1
NICE NG28 (2026)2026年10月26日Fetched https://www.nice.org.uk/guidance/ng28/chapter/Initial-medicines; chapter Initial medicines指南1

待解决的问题

DKA incidence in people who combine SGLT2 inhibitors with prolonged fasting or the Tayebat diet has not been studied.

核查深度如何？

17 项相关研究：8 项核查了全文（其中 4 项进行了结构化偏倚风险评估），9 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。

最近一次科学审核: 2026年10月26日

评定结论的变更历史
  1. 2026年10月25日 · 第 1 阶段 · 初始评估: 基本正确 (中)
  2. 2026年10月26日 · 第 4 阶段（系统证据审查） · 评定结论已更改: 基本正确 (中) → 正确 (高)
    The previous downgrade from TRUE was justified by the use of this fact to argue net harm; that argument belongs to C-ODD-06 (rated FALSE). Judged on its own wording, the claim is correct, and the evidence base now includes a high-certainty RCT network meta-analysis (I-ODD-107), a meta-analysis of 13 large blinded trials (I-ODD-106), dapagliflozin-specific RCT data (I-ODD-105) and documentation of normal- and low-glucose presentations (I-ODD-104, I-ODD-128).
    新来源: I-ODD-103 I-ODD-104 I-ODD-105 I-ODD-106 I-ODD-107 I-ODD-128 I-ODD-129 I-ODD-126

通俗解释

像Forxiga这样的药物会让身体通过尿液排出糖分。在少数情况下，这可能导致危险的酸性物质积聚（酮症酸中毒），而发生时血糖可能看起来正常甚至偏低，尤其是在禁食、生病或采用极低碳水化合物饮食期间。大型试验表明，风险约增加一倍，但仍然很小，5年内每1,000人约多2例。与此同时，这些药物能减少高风险人群的心力衰竭、肾衰竭和死亡。任何正在使用这些药物的人，如果感到不适、呕吐或呼吸急促，即使血糖看起来正常，也应就医并检查酮体。

与该说法相关的研究

支持该说法的研究 (12)

  • Ketoacidosis with canagliflozin

    Erondu N et al.. Diabetes Care 2015 · PMID 26203064 · DOI 10.2337/dc15-1251
    其他被 Tayebat 档案网站引用全文，含结构化偏倚风险评估

    Ketoacidosis was rare (7 per 10,000 patients), often with insulin deficiency or triggers.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Incidence of DKA with canagliflozin

    研究是如何开展的？

    Pooled safety analysis of randomised trials

    研究了多少人、动物或样本？

    17,596; Type 2 diabetes in canagliflozin program

    实际发现了什么？

    DKA 0.07%.

    观察到的效应有多大？

    0.52-0.76 vs 0.24 per 1,000 PY

    研究结果对日常生活意味着什么？

    Rare but real risk.

    该研究有哪些局限？

    Analysed and written by manufacturer employees; only 12 cases; based on investigator reports (may miss cases).

    它对 Elawady 的具体说法说明了什么？

    Supports C-ODD-02; mixed for C-INS-08.

    研究结果是否适用于德国和欧洲？

    Multinational/US/UK data; transferable to EU practice.

    从该研究中明确不能得出什么结论？

    Precise relative risk; that euglycaemic DKA is common (cases here had high glucose).

    科学细节 →

  • Ketoacidosis after starting SGLT2 drugs (letter)

    Fralick M et al.. N Engl J Med 2017 · PMID 28591538 · DOI 10.1056/NEJMc1701990
    队列研究被 Tayebat 档案网站引用已核查摘要

    Content not verified (no abstract).

    该研究是否支持这一具体说法？ 不明确 · 方法学质量: 低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Risk of DKA after initiating an SGLT2 inhibitor (per title)

    研究是如何开展的？

    Research letter (no abstract in PubMed; full text not accessed)

    研究了多少人、动物或样本？

    not verifiable; not verifiable

    实际发现了什么？

    Not verified.

    观察到的效应有多大？

    not verified

    研究结果对日常生活意味着什么？

    See I-ODD-09.

    该研究有哪些局限？

    Not read; letter format

    它对 Elawady 的具体说法说明了什么？

    Supports C-ODD-02 (direction).

    研究结果是否适用于德国和欧洲？

    US data.

    从该研究中明确不能得出什么结论？

    Anything quantitative.

    科学细节 →

  • SGLT2 drugs and ketoacidosis

    Douros A et al.. Ann Intern Med 2020 · PMID 32716707 · DOI 10.7326/M20-0289
    队列研究独立交叉核查已核查摘要★ 关键研究

    About 2 per 1,000 users per year developed ketoacidosis, nearly 3 times more than with DPP-4 drugs.

    该研究是否支持这一具体说法？ 是 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    SGLT2 vs DPP-4 inhibitors and DKA risk

    研究是如何开展的？

    Multicentre population-based cohort (prevalent new-user design, propensity-matched)

    研究了多少人、动物或样本？

    208,757 matched pairs; Type 2 diabetes new users

    实际发现了什么？

    HR 2.85.

    观察到的效应有多大？

    HR 2.85 (1.99-4.08)

    研究结果对日常生活意味着什么？

    Rare but real; caution with fasting/illness.

    该研究有哪些局限？

    No lab data; Unmeasured confounding

    它对 Elawady 的具体说法说明了什么？

    Supports C-ODD-02; relevant to C-FAST-03.

    研究结果是否适用于德国和欧洲？

    UK data included.

    从该研究中明确不能得出什么结论？

    That the drugs are net harmful.

    科学细节 →

  • Ketoacidosis with normal blood sugar on SGLT2 drugs

    Peters AL et al.. Diabetes Care 2015 · PMID 26078479 · DOI 10.2337/dc15-0843
    病例系列 / 病例报告独立交叉核查全文，含结构化偏倚风险评估

    Several patients developed ketoacidosis with near-normal sugar, so it was recognised late.

    该研究是否支持这一具体说法？ 是 · 方法学质量: 极低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Describe euglycaemic DKA with SGLT2 inhibitors

    研究是如何开展的？

    Case series

    研究了多少人、动物或样本？

    9 individuals, 13 episodes; Patients with T1D or T2D on SGLT2 inhibitors

    实际发现了什么？

    13 episodes in 9 patients on canagliflozin (7 with off-label type 1 diabetes); glucose often near normal, delaying diagnosis; all recovered with IV fluids and insulin.

    观察到的效应有多大？

    not applicable

    研究结果对日常生活意味着什么？

    Check ketones when unwell on SGLT2 drugs.

    该研究有哪些局限？

    Incidental case collection, no denominator, mostly off-label type 1 use, all on canagliflozin.

    它对 Elawady 的具体说法说明了什么？

    Supports C-ODD-02; key for C-FAST-03 safety.

    研究结果是否适用于德国和欧洲？

    US.

    从该研究中明确不能得出什么结论？

    How often this happens; that every SGLT2 inhibitor (e.g. dapagliflozin) carries the same risk (inferred, not shown here).

    科学细节 →

  • ADA guideline 2026: blood sugar goals and emergencies

    American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    Most adults should aim for HbA1c below 7%, avoid low sugar, and measure ketones when at risk.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Glycaemic goals, hypoglycaemia and hyperglycaemic crises

    研究是如何开展的？

    Clinical practice guideline (ADA Standards of Care 2026, Section 6)

    研究了多少人、动物或样本？

    not applicable; People with diabetes

    实际发现了什么？

    Individual targets; do not stop basal insulin when not eating.

    观察到的效应有多大？

    not applicable

    研究结果对日常生活意味着什么？

    Moderate targets and safety rules.

    该研究有哪些局限？

    US-centred; Partially read

    它对 Elawady 的具体说法说明了什么？

    Supports C-INS-04, C-INS-11; contradicts C-FAST-01, C-FAST-03, C-DIAB-02.

    研究结果是否适用于德国和欧洲？

    Consistent with EASD guidance.

    从该研究中明确不能得出什么结论？

    Not applicable.

    科学细节 →

  • Canagliflozin in diabetic kidney disease

    Perkovic V et al.. N Engl J Med 2019 · PMID 30990260 · DOI 10.1056/NEJMoa1811744
    随机对照试验独立交叉核查全文，含结构化偏倚风险评估★ 关键研究

    Kidney failure and heart problems fell by about a third; amputations and fractures were not increased, but rare ketoacidosis was more common (11 vs 1 cases).

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Canagliflozin and renal outcomes in type 2 diabetes with nephropathy

    研究是如何开展的？

    Double-blind placebo-controlled RCT (CREDENCE)

    研究了多少人、动物或样本？

    4,401; Type 2 diabetes with albuminuric CKD

    实际发现了什么？

    Primary kidney/heart outcome 43.2 vs 61.2 per 1000 patient-years (30% lower); amputation 12.3 vs 11.2 per 1000 patient-years (not significant); diabetic ketoacidosis 2.2 vs 0.2 per 1000 patient-years.

    观察到的效应有多大？

    HR 0.70

    研究结果对日常生活意味着什么？

    This drug class protects heart and/or kidneys in the studied patients.

    该研究有哪些局限？

    Industry funded; stopped early for benefit; selected high-risk population; foot checks added during the trial may have lowered amputation risk; rare harms imprecise.

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-ODD-06; limits amputation/fracture signals in C-ODD-05.

    研究结果是否适用于德国和欧洲？

    Multinational trial including European sites or directly applicable to EU practice.

    从该研究中明确不能得出什么结论？

    Benefit in low-risk people; absence of side effects (ketoacidosis was increased); amputation safety in routine care without foot surveillance.

    科学细节 →

  • SGLT2 drugs roughly double the rare risk of ketoacidosis

    Colacci M et al.. Can J Diabetes 2022 · PMID 34116926 · DOI 10.1016/j.jcjd.2021.04.006
    Meta分析独立交叉核查已核查摘要★ 关键研究

    RCTs: RR 2.46; absolute risk about 0.6-2.2 cases per 1,000 patient-years.

    RR 2.46 in RCTs, 1.74 in cohorts.

    该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Quantify DKA risk with SGLT2 inhibitors.

    研究是如何开展的？

    Meta-analysis of trials and cohorts.

    研究了多少人、动物或样本？

    About 360,000 participants.

    实际发现了什么？

    Higher DKA risk in trials and cohorts.

    观察到的效应有多大？

    RR 2.46 (1.16-5.21) RCTs; RR 1.74 (1.07-2.83) cohorts.

    研究结果对日常生活意味着什么？

    Rare but real; patients need sick-day rules and ketone checks.

    该研究有哪些局限？

    Few trials, few events.

    它对 Elawady 的具体说法说明了什么？

    Supports the ketoacidosis part of the claim.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    It does not show the drugs are net harmful.

    科学细节 →

  • Ketoacidosis on SGLT2 drugs often comes with only mildly raised sugar

    Sharma A et al.. Diabetes Obes Metab 2025 · PMID 40919651 · DOI 10.1111/dom.70098
    队列研究独立交叉核查已核查摘要

    Published cases had median glucose 10.6 mmol/L despite severe acidosis (pH 7.1).

    Median admission glucose 10.6 mmol/L in 1,024 published cases; lower glucose than in non-users.

    该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Describe DKA in SGLT2 inhibitor users.

    研究是如何开展的？

    UK hospital cohort and review of published cases.

    研究了多少人、动物或样本？

    1,060 admissions; 1,024 published cases.

    实际发现了什么？

    Lower glucose and more acidosis in SGLT2i users; similar outcomes.

    观察到的效应有多大？

    Median glucose 10.6 mmol/L; 21% ICU.

    研究结果对日常生活意味着什么？

    Normal-looking sugar does not exclude ketoacidosis in people on these drugs.

    该研究有哪些局限？

    No incidence data.

    它对 Elawady 的具体说法说明了什么？

    Supports the 'normal glucose' part.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    How often DKA occurs.

    科学细节 →

  • Forxiga in 17,160 people: fewer heart-failure admissions, rare ketoacidosis

    Wiviott SD et al.. N Engl J Med 2019 · PMID 30415602 · DOI 10.1056/NEJMoa1812389
    随机对照试验独立交叉核查已核查摘要★ 关键研究

    HF hospitalisation HR 0.73; renal events HR 0.76; DKA 0.3% vs 0.1%.

    DKA 0.3% vs 0.1% with dapagliflozin in a blinded RCT.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Test cardiovascular safety and benefit of dapagliflozin.

    研究是如何开展的？

    Blinded RCT vs placebo.

    研究了多少人、动物或样本？

    17,160 adults with type 2 diabetes.

    实际发现了什么？

    No change in heart attacks/strokes; fewer heart-failure hospitalisations and kidney events; slightly more DKA and genital infections.

    观察到的效应有多大？

    HHF HR 0.73 (0.61-0.88); DKA +0.2 percentage points.

    研究结果对日常生活意味着什么？

    The drug helps the heart and kidneys; a rare ketoacidosis risk requires precautions.

    该研究有哪些局限？

    Industry-funded; few DKA events.

    它对 Elawady 的具体说法说明了什么？

    Supports the DKA part (C-ODD-02); contradicts 'dirtiest drug' and net harm (C-ODD-06).

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    Risk during prolonged fasting.

    科学细节 →

  • 13 large trials: SGLT2 drugs protect kidneys and heart; ketoacidosis rare

    Nuffield Department of Population Health Renal Studies Group; SMART-C Consortium. Lancet 2022 · PMID 36351458 · DOI 10.1016/S0140-6736(22)02074-8
    Meta分析独立交叉核查已核查全文★ 关键研究

    Kidney progression -37%, CV death -14%; DKA risk doubled from about 0.2 per 1,000 patient-years.

    DKA RR 2.12 in people with diabetes.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Pool all large placebo-controlled SGLT2 inhibitor trials.

    研究是如何开展的？

    Collaborative meta-analysis of 13 blinded RCTs.

    研究了多少人、动物或样本？

    90,409 participants.

    实际发现了什么？

    Clear kidney and heart benefits; DKA doubled but rare; amputation signal mainly from one trial.

    观察到的效应有多大？

    RR 0.63 kidney; RR 0.86 CV death; DKA RR 2.12.

    研究结果对日常生活意味着什么？

    For 1,000 people with diabetes and kidney disease treated for a year, about 26 serious events are avoided and about 2 caused.

    该研究有哪些局限？

    Summary data; industry trials.

    它对 Elawady 的具体说法说明了什么？

    Confirms DKA risk, refutes net harm.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    Effects in people following prolonged fasting regimens.

    科学细节 →

  • 816 trials: what each diabetes drug class does and does not do

    Shi Q et al.. BMJ 2023 · PMID 37024129 · DOI 10.1136/bmj-2022-074068
    Meta分析独立交叉核查已核查全文★ 关键研究

    SGLT2 inhibitors and GLP-1 agonists reduce death by about 12%; each class has specific side effects.

    DKA OR 2.07, high certainty.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Compare benefits and harms of all diabetes drug classes.

    研究是如何开展的？

    Network meta-analysis of 816 RCTs with GRADE.

    研究了多少人、动物或样本？

    471,038 patients.

    实际发现了什么？

    Mortality benefit for SGLT2i and GLP-1 RA; class-specific harms such as DKA and genital infections (SGLT2i), hypoglycaemia (sulfonylureas, insulin), heart failure (TZDs).

    观察到的效应有多大？

    Death OR 0.88; DKA OR 2.07; amputation OR 1.27.

    研究结果对日常生活意味着什么？

    No drug is free of side effects; for several classes the benefits clearly outweigh them in people at risk.

    该研究有哪些局限？

    Low certainty for older drugs.

    它对 Elawady 的具体说法说明了什么？

    Supports 'every class has harms'; refutes 'net harmful'.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    Individual treatment choice.

    科学细节 →

  • Ketoacidosis with low blood sugar on SGLT2 drugs: rare published cases, often after fasting

    Itagaki H et al.. J Clin Med 2026 · PMID 42882058 · DOI 10.3390/jcm15197595
    病例系列 / 病例报告独立交叉核查已核查摘要

    15 cases, median glucose 68 mg/dL; fasting or poor intake in 11 of 15.

    15 published cases with glucose <100 mg/dL; fasting precipitant in 11/15.

    该研究是否支持这一具体说法？ 是 · 方法学质量: 极低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Describe ketoacidosis at low glucose in SGLT2 inhibitor users.

    研究是如何开展的？

    Systematic review of case reports.

    研究了多少人、动物或样本？

    15 cases.

    实际发现了什么？

    Severe acidosis despite low sugar; fasting the main trigger.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    On these drugs, a normal or low sugar reading does not rule out a dangerous acid build-up, especially when fasting.

    该研究有哪些局限？

    Very small, case-based.

    它对 Elawady 的具体说法说明了什么？

    Supports the 'low glucose' part.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    How often it happens.

    科学细节 →

与该说法相矛盾或限制该说法的研究 (4)

  • Empagliflozin heart trial

    Zinman B et al.. N Engl J Med 2015 · PMID 26378978 · DOI 10.1056/NEJMoa1504720
    随机对照试验独立交叉核查已核查摘要★ 关键研究

    Deaths fell from 8.3% to 5.7% over about 3 years.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    CV outcomes of empagliflozin in type 2 diabetes at high CV risk

    研究是如何开展的？

    Double-blind placebo-controlled RCT (EMPA-REG OUTCOME)

    研究了多少人、动物或样本？

    7,020; Type 2 diabetes with high CV risk

    实际发现了什么？

    Primary 10.

    观察到的效应有多大？

    HR 0.86; death -32%

    研究结果对日常生活意味着什么？

    This drug class protects heart and/or kidneys in the studied patients.

    该研究有哪些局限？

    Industry funded; Selected high-risk population

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-ODD-06; context for C-ODD-02, C-ODD-08.

    研究结果是否适用于德国和欧洲？

    Multinational trial including European sites or directly applicable to EU practice.

    从该研究中明确不能得出什么结论？

    Benefit in low-risk people; absence of side effects.

    科学细节 →

  • Dapagliflozin (Forxiga) in kidney disease

    Heerspink HJL et al.. N Engl J Med 2020 · PMID 32970396 · DOI 10.1056/NEJMoa2024816
    随机对照试验独立交叉核查全文，含结构化偏倚风险评估★ 关键研究

    Forxiga reduced kidney failure and deaths; the trial was stopped early because the benefit was clear.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Dapagliflozin in CKD with/without diabetes

    研究是如何开展的？

    Double-blind placebo-controlled RCT (DAPA-CKD)

    研究了多少人、动物或样本？

    4,304; CKD (eGFR 25-75, albuminuria)

    实际发现了什么？

    Kidney failure, kidney decline or kidney/heart death: 9.2% with dapagliflozin vs 14.5% with placebo; deaths 4.7% vs 6.8%. Amputations 1.6% vs 1.8%; no ketoacidosis cases with dapagliflozin (2 with placebo).

    观察到的效应有多大？

    HR 0.61; death HR 0.69

    研究结果对日常生活意味着什么？

    This drug class protects heart and/or kidneys in the studied patients.

    该研究有哪些局限？

    Industry funded; stopped early for benefit (can overstate effect); selected high-risk CKD population; type 1 diabetes excluded; median 2.4 years follow-up.

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-ODD-06 (Forxiga 'kills'); context for C-ODD-02.

    研究结果是否适用于德国和欧洲？

    Multinational trial including European sites or directly applicable to EU practice.

    从该研究中明确不能得出什么结论？

    Benefit in low-risk people; absence of side effects.

    科学细节 →

  • Dapagliflozin in heart failure

    McMurray JJV et al.. N Engl J Med 2019 · PMID 31535829 · DOI 10.1056/NEJMoa1911303
    随机对照试验独立交叉核查已核查摘要★ 关键研究

    Fewer heart failure worsenings and deaths with Forxiga.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Dapagliflozin in heart failure with reduced EF

    研究是如何开展的？

    Double-blind placebo-controlled RCT (DAPA-HF)

    研究了多少人、动物或样本？

    4,744; HFrEF NYHA II-IV, EF <=40%, with/without diabetes

    实际发现了什么？

    Primary 16.

    观察到的效应有多大？

    HR 0.74; death HR 0.83

    研究结果对日常生活意味着什么？

    This drug class protects heart and/or kidneys in the studied patients.

    该研究有哪些局限？

    Industry funded; Selected high-risk population

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-ODD-06.

    研究结果是否适用于德国和欧洲？

    Multinational trial including European sites or directly applicable to EU practice.

    从该研究中明确不能得出什么结论？

    Benefit in low-risk people; absence of side effects.

    科学细节 →

  • Egypt: no ketoacidosis in 61 patients starting SGLT2 drugs during Ramadan

    Khalil HAM et al.. J Diabetes Res 2025 · PMID 40322737 · DOI 10.1155/jdr/4321423
    队列研究独立交叉核查已核查全文

    No DKA, hypoglycaemia or dehydration under supervision; study small and uncontrolled.

    No DKA among 61 Egyptian patients starting SGLT2i during supervised Ramadan fasting; too small to exclude a rare risk.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Test SGLT2 inhibitor safety during Ramadan in Egypt.

    研究是如何开展的？

    Prospective before-after cohort.

    研究了多少人、动物或样本？

    61 patients.

    实际发现了什么？

    Better glucose control; no DKA.

    观察到的效应有多大？

    0/61 DKA.

    研究结果对日常生活意味着什么？

    With medical supervision and education, fasting on these drugs went without ketoacidosis in this small group.

    该研究有哪些局限？

    Small, no control group.

    它对 Elawady 的具体说法说明了什么？

    Limits but does not refute the claim.

    研究结果是否适用于德国和欧洲？

    Moderate.

    从该研究中明确不能得出什么结论？

    That the DKA risk is zero.

    科学细节 →

结果不一或不明确的研究 (1)

  • NICE 2026: offer metformin plus an SGLT-2 inhibitor to most adults with type 2 diabetes

    National Institute for Health and Care Excellence (NICE). NICE guideline 2026
    指南 / 立场声明独立交叉核查已核查摘要★ 关键研究

    Fewer heart events and heart-failure admissions; DKA and Fournier gangrene 1 per 1,000 or fewer.

    Acknowledges DKA as a rare risk (<=1 per 1,000).

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Recommend first-line diabetes medicines.

    研究是如何开展的？

    Guideline based on meta-analyses.

    研究了多少人、动物或样本？

    Not applicable.

    实际发现了什么？

    Benefits outweigh risks for most people.

    观察到的效应有多大？

    HF hospitalisation 54 vs 26-40 per 1,000 over 3 years.

    研究结果对日常生活意味着什么？

    These medicines are recommended because they prevent heart problems.

    该研究有哪些局限？

    UK context.

    它对 Elawady 的具体说法说明了什么？

    Contradicts net harm.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    Individual choices.

    科学细节 →

地区背景

德国 / 欧盟

EMA/BfArM product information for SGLT2 inhibitors carries the same DKA warning (not separately fetched).

埃及

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

在我的国家适用什么？

一般科学评估

正确 正确：达格列净等SGLT2抑制剂会使原本罕见的酮症酸中毒风险增加约一倍，这种酮症酸中毒可能在血糖正常甚至偏低时发生，尤其是在禁食期间；这要求采取预防措施，而不是回避一种已被证实有益的药物。

该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。

参考文献

  1. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.. Erondu N et al.. Diabetes Care 2015 · PMID 26203064 · DOI 10.2337/dc15-1251
  2. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.. Fralick M et al.. N Engl J Med 2017 · PMID 28591538 · DOI 10.1056/NEJMc1701990
  3. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.. Douros A et al.. Ann Intern Med 2020 · PMID 32716707 · DOI 10.7326/M20-0289
  4. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.. Peters AL et al.. Diabetes Care 2015 · PMID 26078479 · DOI 10.2337/dc15-0843
  5. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
  6. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.. Perkovic V et al.. N Engl J Med 2019 · PMID 30990260 · DOI 10.1056/NEJMoa1811744
  7. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.. Colacci M et al.. Can J Diabetes 2022 · PMID 34116926 · DOI 10.1016/j.jcjd.2021.04.006
  8. Clinical characteristics and outcomes of diabetes-related ketoacidosis (DKA) in sodium-glucose co-transporter-2 inhibitor (SGLT2i) users with type 2 diabetes.. Sharma A et al.. Diabetes Obes Metab 2025 · PMID 40919651 · DOI 10.1111/dom.70098
  9. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.. Wiviott SD et al.. N Engl J Med 2019 · PMID 30415602 · DOI 10.1056/NEJMoa1812389
  10. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.. Nuffield Department of Population Health Renal Studies Group; SMART-C Consortium. Lancet 2022 · PMID 36351458 · DOI 10.1016/S0140-6736(22)02074-8
  11. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.. Shi Q et al.. BMJ 2023 · PMID 37024129 · DOI 10.1136/bmj-2022-074068
  12. Ketoacidosis at Hypoglycemic and Low Glucose Levels Associated with SGLT2 Inhibitor Use: A Descriptive Systematic Review of Published Cases.. Itagaki H et al.. J Clin Med 2026 · PMID 42882058 · DOI 10.3390/jcm15197595
  13. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.. Zinman B et al.. N Engl J Med 2015 · PMID 26378978 · DOI 10.1056/NEJMoa1504720
  14. Dapagliflozin in Patients with Chronic Kidney Disease.. Heerspink HJL et al.. N Engl J Med 2020 · PMID 32970396 · DOI 10.1056/NEJMoa2024816
  15. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.. McMurray JJV et al.. N Engl J Med 2019 · PMID 31535829 · DOI 10.1056/NEJMoa1911303
  16. First-Time Usage of SGLT2 Inhibitors in Patients With Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety.. Khalil HAM et al.. J Diabetes Res 2025 · PMID 40322737 · DOI 10.1155/jdr/4321423
  17. Type 2 diabetes in adults: management (NICE guideline NG28), published 2 December 2015, last updated 18 February 2026. National Institute for Health and Care Excellence (NICE). NICE guideline 2026

← 返回概览